- PMCB Dashboard
-
Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
PharmaCyte Biotech (PMCB) Financial statements
Company Profile
Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | ||
---|---|---|---|---|---|
Total Revenue | |||||
Cost of Revenue | |||||
Gross Profit | |||||
Gross Profit Margin (%) | |||||
R&D Expense | |||||
SG&A Expense | |||||
Total Operating Expenses | |||||
Operating Income or Loss | |||||
Operating Margin (%) | |||||
Interest Expense | |||||
Total Other Income/Expenses | |||||
Income Before Tax | |||||
Income Tax Expense | |||||
Income from Continuing Ops. | |||||
Net Income | |||||
Net Profit Margin (%) | |||||
Net Income Available to Common Shareholders | |||||
Basic EPS | |||||
Diluted EPS | |||||
Basic Average Shares | |||||
Diluted Average Shares |
Oct 2024 | Jul 2024 | Jan 2024 | Oct 2023 | Jul 2023 | Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | Apr 2022 | Jan 2022 | Oct 2021 | Jul 2021 | Apr 2021 | Jan 2021 | Oct 2020 | Jul 2020 | Apr 2020 | Jan 2020 | Oct 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | |||||||||||||||||||||
Cost of Revenue | |||||||||||||||||||||
Gross Profit | |||||||||||||||||||||
Gross Profit Margin (%) | |||||||||||||||||||||
R&D Expense | |||||||||||||||||||||
SG&A Expense | |||||||||||||||||||||
Total Operating Expenses | |||||||||||||||||||||
Operating Income or Loss | |||||||||||||||||||||
Operating Margin (%) | |||||||||||||||||||||
Interest Expense | |||||||||||||||||||||
Total Other Income/Expenses | |||||||||||||||||||||
Income Before Tax | |||||||||||||||||||||
Income Tax Expense | |||||||||||||||||||||
Income from Continuing Ops. | |||||||||||||||||||||
Net Income | |||||||||||||||||||||
Net Profit Margin (%) | |||||||||||||||||||||
Net Income Available to Common Shareholders | |||||||||||||||||||||
Basic EPS | |||||||||||||||||||||
Diluted EPS | |||||||||||||||||||||
Basic Average Shares | |||||||||||||||||||||
Diluted Average Shares |
Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | ||
---|---|---|---|---|---|
Current Assets | |||||
Cash & Cash Equivalents | |||||
Marketable Securities | |||||
Receivables | |||||
Inventories | |||||
Other Current Assets | |||||
Total Current Assets | |||||
Non-Current Assets | |||||
Marketable Securities | |||||
PPE Net | |||||
Intangibles inc. Goodwill | |||||
Other Non-Current Assets | |||||
Total Non-Current Assets | |||||
Total Assets | |||||
Current Liabilities | |||||
Accounts Payable | |||||
Deferred Revenues | |||||
Debt, Current | |||||
Accrued Liabilities | |||||
Other Current Liabilities | |||||
Total Current Liabilities | |||||
Non-Current Liabilities | |||||
Deferred Revenues | |||||
Debt, Non-Current | |||||
Other Non-Current Liabilities | |||||
Total Non-Current Liabilities | |||||
Total Liabilities | |||||
Shareholders' Equity | |||||
Common Stock | |||||
Additional Paid-In Capital | |||||
Retained Earnings | |||||
Other Shareholders' Equity | |||||
Total Shareholders' Equity | |||||
Total Liabilities & Shareholders' Equity |
Oct 2024 | Jul 2024 | Jan 2024 | Oct 2023 | Jul 2023 | Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | Apr 2022 | Jan 2022 | Oct 2021 | Jul 2021 | Apr 2021 | Jan 2021 | Oct 2020 | Jul 2020 | Apr 2020 | Jan 2020 | Oct 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Current Assets | |||||||||||||||||||||
Cash & Cash Equivalents | |||||||||||||||||||||
Marketable Securities | |||||||||||||||||||||
Receivables | |||||||||||||||||||||
Inventories | |||||||||||||||||||||
Other Current Assets | |||||||||||||||||||||
Total Current Assets | |||||||||||||||||||||
Non-Current Assets | |||||||||||||||||||||
Marketable Securities | |||||||||||||||||||||
PPE Net | |||||||||||||||||||||
Intangibles inc. Goodwill | |||||||||||||||||||||
Other Non-Current Assets | |||||||||||||||||||||
Total Non-Current Assets | |||||||||||||||||||||
Total Assets | |||||||||||||||||||||
Current Liabilities | |||||||||||||||||||||
Accounts Payable | |||||||||||||||||||||
Deferred Revenues | |||||||||||||||||||||
Debt, Current | |||||||||||||||||||||
Accrued Liabilities | |||||||||||||||||||||
Other Current Liabilities | |||||||||||||||||||||
Total Current Liabilities | |||||||||||||||||||||
Non-Current Liabilities | |||||||||||||||||||||
Deferred Revenues | |||||||||||||||||||||
Debt, Non-Current | |||||||||||||||||||||
Other Non-Current Liabilities | |||||||||||||||||||||
Total Non-Current Liabilities | |||||||||||||||||||||
Total Liabilities | |||||||||||||||||||||
Shareholders' Equity | |||||||||||||||||||||
Common Stock | |||||||||||||||||||||
Additional Paid-In Capital | |||||||||||||||||||||
Retained Earnings | |||||||||||||||||||||
Other Shareholders' Equity | |||||||||||||||||||||
Total Shareholders' Equity | |||||||||||||||||||||
Total Liabilities & Shareholders' Equity |
Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | ||
---|---|---|---|---|---|
Cash Flows from Operating Activities | |||||
Net Income | |||||
Depreciation & Amortization | |||||
Deferred Income Taxes | |||||
Stock Based Compensation | |||||
Accounts Receivable | |||||
Inventory | |||||
Accounts Payable | |||||
Deferred Revenue | |||||
Other Non-Cash | |||||
Operating Cash Flow | |||||
Cash Flows from Investing Activities | |||||
PPE Investments | |||||
Net Acquisitions | |||||
Purchase of Investments | |||||
Sale of Investments | |||||
Other Investing Activity | |||||
Investing Cash Flow | |||||
Cash Flows from Financing Activities | |||||
Debt Issued | |||||
Proceeds from Debt Repayment | |||||
Debt Repayment | |||||
Proceeds from Sale of Equity | |||||
Equity Repurchased | |||||
Dividend Paid | |||||
Other Financing Activity | |||||
Financing Cash Flow | |||||
Cash Position | |||||
Beginning Cash Position | |||||
End Cash Position | |||||
Change in Cash | |||||
Free Cash Flow | |||||
Operating Cash Flow | |||||
Capital Expenditure | |||||
Free Cash Flow |
Oct 2024 | Jul 2024 | Jan 2024 | Oct 2023 | Jul 2023 | Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | Apr 2022 | Jan 2022 | Oct 2021 | Jul 2021 | Apr 2021 | Jan 2021 | Oct 2020 | Jul 2020 | Apr 2020 | Jan 2020 | Oct 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash Flows from Operating Activities | |||||||||||||||||||||
Net Income | |||||||||||||||||||||
Depreciation & Amortization | |||||||||||||||||||||
Deferred Income Taxes | |||||||||||||||||||||
Stock Based Compensation | |||||||||||||||||||||
Accounts Receivable | |||||||||||||||||||||
Inventory | |||||||||||||||||||||
Accounts Payable | |||||||||||||||||||||
Deferred Revenue | |||||||||||||||||||||
Other Non-Cash | |||||||||||||||||||||
Operating Cash Flow | |||||||||||||||||||||
Cash Flows from Investing Activities | |||||||||||||||||||||
PPE Investments | |||||||||||||||||||||
Net Acquisitions | |||||||||||||||||||||
Purchase of Investments | |||||||||||||||||||||
Sale of Investments | |||||||||||||||||||||
Other Investing Activity | |||||||||||||||||||||
Investing Cash Flow | |||||||||||||||||||||
Cash Flows from Financing Activities | |||||||||||||||||||||
Debt Issued | |||||||||||||||||||||
Proceeds from Debt Repayment | |||||||||||||||||||||
Debt Repayment | |||||||||||||||||||||
Proceeds from Sale of Equity | |||||||||||||||||||||
Equity Repurchased | |||||||||||||||||||||
Dividend Paid | |||||||||||||||||||||
Other Financing Activity | |||||||||||||||||||||
Financing Cash Flow | |||||||||||||||||||||
Cash Position | |||||||||||||||||||||
Beginning Cash Position | |||||||||||||||||||||
End Cash Position | |||||||||||||||||||||
Change in Cash | |||||||||||||||||||||
Free Cash Flow | |||||||||||||||||||||
Operating Cash Flow | |||||||||||||||||||||
Capital Expenditure | |||||||||||||||||||||
Free Cash Flow |